HomeCompareCHGCF vs BTI

CHGCF vs BTI: Dividend Comparison 2026

CHGCF yields 2.90% · BTI yields 5.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHGCF wins by $350.23M in total portfolio value· pulled ahead in Year 2
10 years
CHGCF
CHGCF
● Live price
2.90%
Share price
$55.78
Annual div
$1.62
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$350.27M
Annual income
$328,490,171.71
Full CHGCF calculator →
BTI
BTI
● Live price
5.40%
Share price
$58.26
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.8K
Annual income
$2,802.29
Full BTI calculator →

Portfolio growth — CHGCF vs BTI

📍 CHGCF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHGCFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHGCF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHGCF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHGCF
Annual income on $10K today (after 15% tax)
$246.26/yr
After 10yr DRIP, annual income (after tax)
$279,216,645.95/yr
BTI
Annual income on $10K today (after 15% tax)
$459.05/yr
After 10yr DRIP, annual income (after tax)
$2,381.95/yr
At 15% tax rate, CHGCF beats the other by $279,214,264.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHGCF + BTI for your $10,000?

CHGCF: 50%BTI: 50%
100% BTI50/50100% CHGCF
Portfolio after 10yr
$175.15M
Annual income
$164,246,486.99/yr
Blended yield
93.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

CHGCF
No analyst data
Altman Z
21.8
Piotroski
5/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.3% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHGCF buys
0
BTI buys
0
No recent congressional trades found for CHGCF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHGCFBTI
Forward yield2.90%5.40%
Annual dividend / share$1.62$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%11.3%
Portfolio after 10y$350.27M$37.8K
Annual income after 10y$328,490,171.71$2,802.29
Total dividends collected$348.65M$14.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CHGCF vs BTI ($10,000, DRIP)

YearCHGCF PortfolioCHGCF Income/yrBTI PortfolioBTI Income/yrGap
1$11,279$579.45$11,301$601.08$22.00BTI
2← crossover$13,291$1,221.65$12,799$706.58+$492.00CHGCF
3$16,912$2,690.62$14,527$832.38+$2.4KCHGCF
4$24,495$6,399.38$16,527$982.75+$8.0KCHGCF
5$43,534$17,324.98$18,846$1,162.95+$24.7KCHGCF
6$104,136$57,554.30$21,545$1,379.49+$82.6KCHGCF
7$368,757$257,331.25$24,694$1,640.41+$344.1KCHGCF
8$2,097,816$1,703,246.11$28,378$1,955.69+$2.07MCHGCF
9$20,356,014$18,111,350.35$32,702$2,337.79+$20.32MCHGCF
10$350,271,106$328,490,171.71$37,794$2,802.29+$350.23MCHGCF

CHGCF vs BTI: Complete Analysis 2026

CHGCFStock

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Full CHGCF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this CHGCF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHGCF vs SCHDCHGCF vs JEPICHGCF vs OCHGCF vs KOCHGCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.